About us
Founded in 2012 and granted the qualification of biomedicine company by the Ministry of Economic Affairs in 2015, Energenesis Biomedical Co., Ltd. aspires to become a new star in biotech industry.
Information
- 2019-12 The Israeli patent “Compounds for activating AMPK and the uses thereof.” is granted
- 2019-11 The IND application of ENERGI-F703 for treating venous leg ulcers (VLU) has been approved by the US FDA
- 2019-10 The Phase II trial of ENERGI-F703 Diabetic Foot Ulcer Gel meets the primary endpoint. Energenesis is planning phase III clinical trials
- 2019-04 The Australian patent "Compound for activating AMPK and uses thereof" is granted